Article info

Download PDFPDF

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis

Authors

  1. Correspondence to Professor Margreet Kloppenburg, Department of Rheumatology, Leiden University Medical Center, Postbox 9600, Leiden 2300 RC, The Netherlands; g.kloppenburg{at}lumc.nl
View Full Text

Citation

Kloppenburg M, Peterfy C, Haugen IK, et al
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis

Publication history

  • Received March 1, 2018
  • Revised October 26, 2018
  • Accepted October 28, 2018
  • First published December 14, 2018.
Online issue publication 
February 14, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.